drugset / Trial / NCT00195351

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

NCT00195351

Phase 4 Completed 467 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a phase 3b/4 randomized, open-label, comparative, multicenter study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI (Complicated Intra-Abdominal Infection). Subjects with clinical signs and symptoms of cIAI will be included for enrollment. Subjects will be stratified at randomization for Acute Physiologic and Chronic Health Evaluation scale (APACHE II) score \< 10 and \> 10. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).

Timeline

Start
2005-09
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ceftriaxone Other / unclassified 2 g Intravenous
Comparator Metronidazole Small molecule 1 g Intravenous
Comparator Metronidazole Small molecule 2 g Intravenous
Comparator Tigecycline Small molecule 50 mg Intravenous